Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight

A. LeBlanc, T. Matsumoto, J. Jones, Jay Shapiro, T. Lang, L. Shackelford, S. M. Smith, H. Evans, E. Spector, R. Ploutz-Snyder, J. Sibonga, J. Keyak, T. Nakamura, K. Kohri, H. Ohshima

Research output: Contribution to journalArticle

Abstract

We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. Introduction: This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. Methods: We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. Results: In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. Conclusions: The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.

Original languageEnglish (US)
Pages (from-to)2105-2114
Number of pages10
JournalOsteoporosis International
Volume24
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Space Flight
Diphosphonates
Exercise
Bone and Bones
Astronauts
Equipment and Supplies
Hip
Alendronate
Bone Resorption
Tomography
Pelvic Bones
United States National Aeronautics and Space Administration
Bone Density Conservation Agents
Calcium
Densitometry
Femur Neck
Photon Absorptiometry
Pelvis
Bone Density
Spine

Keywords

  • Bisphosphonates
  • Bone loss
  • Computed bone strength
  • Exercise
  • QCT
  • Spaceflight

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. / LeBlanc, A.; Matsumoto, T.; Jones, J.; Shapiro, Jay; Lang, T.; Shackelford, L.; Smith, S. M.; Evans, H.; Spector, E.; Ploutz-Snyder, R.; Sibonga, J.; Keyak, J.; Nakamura, T.; Kohri, K.; Ohshima, H.

In: Osteoporosis International, Vol. 24, No. 7, 07.2013, p. 2105-2114.

Research output: Contribution to journalArticle

LeBlanc, A, Matsumoto, T, Jones, J, Shapiro, J, Lang, T, Shackelford, L, Smith, SM, Evans, H, Spector, E, Ploutz-Snyder, R, Sibonga, J, Keyak, J, Nakamura, T, Kohri, K & Ohshima, H 2013, 'Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight', Osteoporosis International, vol. 24, no. 7, pp. 2105-2114. https://doi.org/10.1007/s00198-012-2243-z
LeBlanc, A. ; Matsumoto, T. ; Jones, J. ; Shapiro, Jay ; Lang, T. ; Shackelford, L. ; Smith, S. M. ; Evans, H. ; Spector, E. ; Ploutz-Snyder, R. ; Sibonga, J. ; Keyak, J. ; Nakamura, T. ; Kohri, K. ; Ohshima, H. / Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. In: Osteoporosis International. 2013 ; Vol. 24, No. 7. pp. 2105-2114.
@article{a3ef453875644b77867162bd6641e243,
title = "Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight",
abstract = "We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. Introduction: This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. Methods: We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. Results: In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. Conclusions: The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.",
keywords = "Bisphosphonates, Bone loss, Computed bone strength, Exercise, QCT, Spaceflight",
author = "A. LeBlanc and T. Matsumoto and J. Jones and Jay Shapiro and T. Lang and L. Shackelford and Smith, {S. M.} and H. Evans and E. Spector and R. Ploutz-Snyder and J. Sibonga and J. Keyak and T. Nakamura and K. Kohri and H. Ohshima",
year = "2013",
month = "7",
doi = "10.1007/s00198-012-2243-z",
language = "English (US)",
volume = "24",
pages = "2105--2114",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "7",

}

TY - JOUR

T1 - Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight

AU - LeBlanc, A.

AU - Matsumoto, T.

AU - Jones, J.

AU - Shapiro, Jay

AU - Lang, T.

AU - Shackelford, L.

AU - Smith, S. M.

AU - Evans, H.

AU - Spector, E.

AU - Ploutz-Snyder, R.

AU - Sibonga, J.

AU - Keyak, J.

AU - Nakamura, T.

AU - Kohri, K.

AU - Ohshima, H.

PY - 2013/7

Y1 - 2013/7

N2 - We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. Introduction: This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. Methods: We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. Results: In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. Conclusions: The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.

AB - We report the results of alendronate ingestion plus exercise in preventing the declines in bone mass and strength and elevated levels of urinary calcium and bone resorption in astronauts during 5.5 months of spaceflight. Introduction: This investigation was an international collaboration between NASA and the JAXA space agencies to investigate the potential value of antiresorptive agents to mitigate the well-established bone changes associated with long-duration spaceflight. Methods: We report the results from seven International Space Station (ISS) astronauts who spent a mean of 5.5 months on the ISS and who took an oral dose of 70 mg of alendronate weekly starting 3 weeks before flight and continuing throughout the mission. All crewmembers had available for exercise a treadmill, cycle ergometer, and a resistance exercise device. Our assessment included densitometry of multiple bone regions using X-ray absorptiometry (DXA) and quantitative computed tomography (QCT) and assays of biomarkers of bone metabolism. Results: In addition to pre- and post-flight measurements, we compared our results to 18 astronauts who flew ISS missions and who exercised using an early model resistance exercise device, called the interim resistance exercise device, and to 11 ISS astronauts who exercised using the newer advanced resistance exercise device (ARED). Our findings indicate that the ARED provided significant attenuation of bone loss compared with the older device although post-flight decreases in the femur neck and hip remained. The combination of the ARED and bisphosphonate attenuated the expected decline in essentially all indices of altered bone physiology during spaceflight including: DXA-determined losses in bone mineral density of the spine, hip, and pelvis, QCT-determined compartmental losses in trabecular and cortical bone mass in the hip, calculated measures of fall and stance computed bone strength of the hip, elevated levels of bone resorption markers, and urinary excretion of calcium. Conclusions: The combination of exercise plus an antiresoptive drug may be useful for protecting bone health during long-duration spaceflight.

KW - Bisphosphonates

KW - Bone loss

KW - Computed bone strength

KW - Exercise

KW - QCT

KW - Spaceflight

UR - http://www.scopus.com/inward/record.url?scp=84879200560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879200560&partnerID=8YFLogxK

U2 - 10.1007/s00198-012-2243-z

DO - 10.1007/s00198-012-2243-z

M3 - Article

C2 - 23334732

AN - SCOPUS:84879200560

VL - 24

SP - 2105

EP - 2114

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 7

ER -